| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Sennoside A (formerly also known as NSC112929; NSC-112929), used as a laxative and an anti-constipation agent, is a naturally occurring dianthrone glycoside compound isolated from Rhei Rhizoma and senna leaf. It can cause purgative actions in the intestine and has been used to clean out the intestines before a bowel examination/surgery. Sennoside A and B have identical molecular weights and formula. Sennosides were known as laxatives causing purgative actions through the biotransformation of rhein anthrone. Sennoside A was reported to have regionally differential effects on spontaneous contractions of colon.
| ln Vitro |
Sennoside A has the ability to inhibit several versions of RDDP and RNase H. It has been observed that IC50s of 78 μM (K103N RT), 21.3 μM (Y181C RT), and 64 μM (Y188L RT) for various variants of RDDP are inhibited. 18.4 μM for N474A RT and 17.7 μM for Q475A RT, respectively, were the IC50s[3]. HIV-1 recombinant CAT virus, pseudotyped with the envelope glycoprotein of the laboratory-adapted T-tropic virus HXBc2, infects Jurka cells. Infected cells' CAT activity is greatly inhibited by sensnoside A (5–20 μM; 72 h)[3].
|
||
|---|---|---|---|
| ln Vivo |
Type 2 diabetes (T2D) mice's gut microbiome composition is changed by sensnoside A (25 mg/kg, 50 mg/kg; intragastric gavage for 12 weeks), which also has anti-obesity effects[3]. In the ileum of genetically faulty animals, sensnoside A also raises tight junction proteins and decreases inflammation[3].
|
||
| Animal Protocol |
|
||
| References |
[1]. Rama Reddy NR, et al. Next Generation Sequencing and Transcriptome Analysis Predicts Biosynthetic Pathway of Sennosides from Senna (Cassia angustifolia Vahl.), a Non-Model Plant with Potent Laxative Properties. PLoS One. 2015 Jun 22;10(6):e0129422.
[2]. Esposito F, et al. Sennoside A, derived from the traditional chinese medicine plant Rheum L., is a new dual HIV-1 inhibitor effective on HIV-1 replication. Phytomedicine. 2016 Nov 15;23(12):1383-1391. |
| Molecular Formula |
C42H38O20
|
|
|---|---|---|
| Molecular Weight |
862.74
|
|
| CAS # |
81-27-6
|
|
| Related CAS # |
|
|
| SMILES |
OC1C(O)C(OC2=C(C(C(C(O)=CC(C(O)=O)=C3)=C3C4C5C(C=CC=C6OC7C(O)C(O)C(O)C(CO)O7)=C6C(C8=C5C=C(C(O)=O)C=C8O)=O)=O)C4=CC=C2)OC(CO)C1O
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 6.25 mg/mL (7.24 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1591 mL | 5.7955 mL | 11.5910 mL | |
| 5 mM | 0.2318 mL | 1.1591 mL | 2.3182 mL | |
| 10 mM | 0.1159 mL | 0.5795 mL | 1.1591 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
